A Phase I Study of MSC-1 in Patients with Advanced Cancers

Full Title

MSC-1-101: A Phase 1 Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Antitumor Activity of MSC-1 in Patients with Advanced Solid Tumors

Purpose

Leukemia inhibitor factor (LIF) is a protein that is found at high levels in many cancers. It is believed to play an important role in the growth and spread of cancer by altering the immune system, making the cancer more difficult to detect and eliminate by the body. MSC-1 is a drug that block the function of LIF.

The purpose of this study is to find the highest dose of MSC-1 that can be given safely in patients with advanced solid tumors. MSC-1 is given intravenously (by vein).

Eligibility

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have an advanced solid tumor that has come back or continued to grow despite standard therapy or for which no standard therapy exists.
  • Patients should recover from the serious side effects of prior therapies.
  • Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Alison Schram at 646-888-5388.

Protocol

18-079

Phase

I

Investigator

Co-Investigators